J&J Stock Dives As FDA Halts Covid Vaccine Use On Blood-Clotting Issue

The Food and Drug Administration halted use of Johnson & Johnson‘s (JNJ) coronavirus vaccine on Tuesday on reports of blood clots in six recipients. In response, JNJ stock tripped.


All six cases occurred in women between the ages of 18 and 48. Symptoms appeared within six to 13 days following vaccination. So far, there have been 6.8 million doses administered in the U.S.

The Centers for Disease Control and Prevention will hold a meeting on Wednesday to review the cases. The FDA will then review that analysis. Until that process is complete, the agencies recommended a complete pause in administering the J&J shot.

In premarket trading, JNJ stock fell 2.9% near 161.60. Competing vaccine makers gained on the news, as Moderna (MRNA) surged 5.5% premarket to 147. BioNTech (BNTX) climbed 2.5% to 124.50 and Pfizer (PFE)added 0.8% to 37.28.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Trouble Is Brewing For J&J’s Covid Vaccine — What You Need To Know

Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader

Options Trading: How To Start Using Options, How To Manage Risk

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button